News

CSHL’s Camila dos Santos scores family’s second $600K award

TBR News Media They aren’t quite wonder twins, but some day the dedicated work of husband and wife scientists Christopher Vakoc and Camila dos Santos may help people batting against a range of cancers, from leukemia to breast cancer. Dos Santos and Vakoc are the first family of prize winners in the Pershing Square Foundation’s … Continued

Read More

Researchers discover new type of lung cancer

Cold Spring Harbor, NY — Researchers have discovered a new kind of small-cell lung cancer (SCLC). The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease. “Cancer is not one thing, it’s actually hundreds of distinct diseases.” This common refrain helps explain the frustrating experience oncologists have … Continued

Read More

SBU’s Benjamin Martin scores first Sohn Research Prize

TBR News Media Up and coming scientists are often stuck in the same position as promising professionals in other fields. To get the funding for research they’d like to do, they need to show results, but to get results, they need funding. Joseph Heller, author of “Catch 22,” would certainly relate. A New York-based philanthropy … Continued

Read More

PRESS RELEASE: SEVEN NEW YORK CITY-AREA SCIENTISTS WIN PERSHING SQUARE SOHN PRIZE FOR YOUNG INVESTIGATORS IN CANCER RESEARCH

SEVEN NEW YORK CITY-AREA SCIENTISTS WIN PERSHING SQUARE SOHN PRIZE FOR YOUNG INVESTIGATORS IN CANCER RESEARCH The Pershing Square Sohn Research Alliance Has Invested $19 million in the Next Generation of New York City Medical Research Talent to Accelerate Breakthroughs in Cancer Research NEW YORK, May 22, 2018 – The Pershing Square Sohn Cancer Research … Continued

Read More

Study reveals a way to make prostate cancer cells run out of energy and die

Cold Spring Harbor, NY – Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered that cells lacking the tumor-suppressor protein PTEN–a feature of many cancers– are particularly vulnerable to drugs that impair their energy-producing mitochondria. Such drugs induce them to literally eat themselves to death, the research shows. Unlike normal cells, cells without PTEN seem … Continued

Read More

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

–Versant-seeded company focused on applying novel biology to boost anti-tumor immunity– —Foundational science stems from landmark ER stress biology research at Weill Cornell Medicine— —Michael Aberman, M.D., former SVP of Strategy for Regeneron, appointed as President and Chief Executive Officer— NEW YORK–(BUSINESS WIRE)–Quentis Therapeutics Inc., a biotechnology company pursuing next-generation immuno-oncology research and drug development, … Continued

Read More

Machine Learning for Building Personalized Cancer Nanomedicines: Interview with Dr. Daniel Heller

Researchers at the Sloan Kettering Institute and the Weill Cornell Graduate School of Medical Sciences in New York have developed a machine learning approach to design personalized nanoparticle therapies for cancer. Personalized cancer therapies aim to provide a treatment that is tailored to the genetic makeup of a patient’s tumor. They can still cause side effects, however, when they … Continued

Read More

Intravital Imaging Offers View of Cancer Cell Interaction With Immune Response

Far from her native Copenhagen, Denmark, Mikala Egeblad, PhD, works tirelessly to find a means to reduce cancer metastases and recurrences. The significance of her work, now centered in her lab at Cold Spring Harbor Laboratory, Long Island, N.Y., where she is an Associate Professor, has resulted in the Department of Defense Breast Cancer Research … Continued

Read More

New immunotherapy approach boosts body’s ability to destroy cancer cells

Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes after infectious microorganisms. Yet these treatments only benefit some patients, and remain ineffective in the vast majority of cases. … Continued

Read More

Throwing molecular wrench into gene control machine leads to ‘melting away’ of leukemia

PUBLIC RELEASE: 8-JAN-2018 Cold Spring Harbor, NY – Cancer researchers today announced they have developed a way of sidelining one of the most dangerous “bad actors” in leukemia. Their approach depends on throwing a molecular wrench into the gears of an important machine that sets genes into motion, enabling cancer cells to proliferate. In tests in … Continued

Read More